ReviewBiochemia medica2013
Serological markers of inflammatory bowel disease.
Review in Biochemia medica, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 2 syntheses or guidelines pooled it, 100 citations in OpenAlex.
- Circulatory resistin levels in inflammatory bowel disease: a systematic review and meta-analysis.BMC gastroenterology · 2024Pooled it
- A systematic review and critical appraisal of metagenomic and culture studies in hidradenitis suppurativa.Experimental dermatology · 2021Pooled it
- Serological profiling of Crohn's disease and ulcerative colitis patients reveals anti-microbial antibody signatures.World journal of gastroenterology · 2022Trial
- Diet, Gut Microbiome, and Microbial Metabolites in Inflammatory Bowel Disease: From Functional Dysbiosis to Precision Nutrition.International journal of molecular sciences · 2026Review
- Imputation methods for serologic biomarkers in inflammatory bowel disease.Scientific reports · 2026Article
- Environmental and Inflammatory Factors Drive Perinuclear-Antineutrophil Cytoplasmic Antibodies (pANCA) in Ulcerative Colitis: A European Twin Study.United European gastroenterology journal · 2025Article
- Prevalence of Anti-Pathogens (Basel, Switzerland) · 2025Article
- Role of Novel Target Molecules (β-Catenin and Retinoblastoma Protein) in the Spectrum of Inflammatory Bowel Disease.Cureus · 2025Article
- Complex dichotomous links of nonalcoholic fatty liver disease and inflammatory bowel disease: exploring risks, mechanisms, and management modalities.Intestinal research · 2024Review
- Review
- Recent Trends in Non-Invasive Methods of Diagnosis and Evaluation of Inflammatory Bowel Disease: A Short Review.International journal of molecular sciences · 2024Review
- Noninvasive Stool RNA Test Approximates Disease Activity in Patients With Crohn's Disease.Gastro hep advances · 2024Article
- Advancing the precision management of inflammatory bowel disease in the era of omics approaches and new technology.World journal of gastroenterology · 2023Review
- Role of Serum Proteinase 3 Antineutrophil Cytoplasmic Antibodies in the Diagnosis, Evaluation of Disease Severity, and Clinical Course of Ulcerative Colitis.Gut and liver · 2022Article
- Autoimmune Diseases of Digestive Organs-A Multidisciplinary Challenge: A Focus on Hepatopancreatobiliary Manifestation.Journal of clinical medicine · 2021Review
- Utility of the combined use of 3 serologic markers in the diagnosis and monitoring of chronic enteropathies in dogs.Journal of veterinary internal medicine · 2021Article
- Expression of Chemokine CCL28 in Ulcerative Colitis Patients.Gut and liver · 2021Article
- Neutrophil Extracellular Traps in Inflammatory Bowel Disease: Pathogenic Mechanisms and Clinical Translation.Cellular and molecular gastroenterology and hepatology · 2021Review
- Review
- Revisiting the gut-joint axis: links between gut inflammation and spondyloarthritis.Nature reviews. Rheumatology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory bowel disease (IBD) is a heterogeneous group of chronic inflammatory disorders of the gastrointestinal tract with two main distinguishable entities, Crohn's disease (CD) and ulcerative colitis (UC). IBD-unclassified (IBD-U) is a diagnosis that covers the "grey" zone of diagnostic uncertainty between UC and CD. Current diagnosis of IBD relies on the clinical, endoscopic, radiological, histological and biochemical features, but this approach has shortcomings especially in cases of overlapping symptoms of CD and UC. The need for a diagnostic tool that would improve the conventional methods in IBD diagnosis directed the search towards potential immunological markers, since an aberrant immune response against microbial or endogenous antigens in a genetically susceptible host seems to be implicated in IBD pathogenesis. The spectrum of antibodies to different microbial antigens and autoantibodies associated with IBD is rapidly expanding. Most of these antibodies are associated with CD like anti-glycan antibodies: anti-Saccharomices cerevisiae (ASCA) and the recently described anti-laminaribioside (ALCA), anti-chitobioside (ACCA), anti-mannobioside (AMCA), anti-laminarin (anti-L) and anti-chitin (anti-C) antibodies; in addition to other antibodies that target microbial antigens: anti-outer membrane porin C (anti-OmpC), anti-Cbir1 flagellin and anti-12 antibody. Also, autoantibodies targeting the exocrine pancreas (PAB) were shown to be highly specific for CD. In contrast, UC has been associated with anti-neutrophil cytoplasmic autoantibodies (pANCA) and antibodies against goblet cells (GAB). Current evidence suggests that serologic panels of multiple antibodies are useful in differential diagnosis of CD versus UC and can be a valuable aid in stratifying patients according to disease phenotype and risk of complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.